M&A / Deals Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Read full story Post navigation Previous: Novo’s CEO champions “record-breaking start” for Wegovy pill in US marketNext: Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy Related Stories M&A / Deals Lilly, Gilead lead pharma’s M&A boom pharminent May 8, 2026 M&A / Deals Angelini inks $4.1B Catalyst buy to enter US rare disease market pharminent May 7, 2026 M&A / Deals Roche buys AI-powered diagnostics player PathAI pharminent May 7, 2026
